Chang Jiang Shang Bao·2026-03-02 00:34Core Insights - After turning profitable, BeiGene (688235.SH, 06160.HK, NASDAQ: BGNE) has demonstrated significant growth momentum, with 2025 revenue reaching 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, recovering from a loss of 4.978 billion yuan in the previous year [2][3] Financial Performance - In 2025, BeiGene's product revenue was 37.77 billion yuan, up 39.9% year-on-year [2] - The company reported a net profit of 1.422 billion yuan for 2025, compared to a loss of 4.978 billion yuan in the same period last year [2] - The company had a cumulative net loss of approximately 59.1 billion yuan from 2017 to 2024, averaging over 20 million yuan in daily losses [2] Revenue Drivers - The growth in product revenue for 2025 was primarily driven by the sales of Baiyueze (Zebutinib), licensed products from Amgen, and Baizean (Tislelizumab) [3][4] - Baiyueze's global sales reached 28.067 billion yuan in 2025, marking a 48.8% increase, solidifying its position as a global leader in the BTK inhibitor market [3] - Sales in the U.S. totaled 20.206 billion yuan, up 45.5%, while Europe and China saw increases of 66.4% and 33.1%, respectively [3] R&D Investment - BeiGene has consistently invested over 10 billion yuan in R&D for four consecutive years, with cumulative R&D expenses reaching 49.264 billion yuan, accounting for approximately 60% of total revenue during this period [6][7] - R&D expenses for 2025's first three quarters were 11.159 billion yuan, a 9.77% increase year-on-year, representing about 40% of the revenue for that period [6] Product Development - Baiyueze is noted for having the broadest range of approved indications among BTK inhibitors globally, with over 45 clinical trials conducted across more than 30 countries [7] - Baizean is positioned as a cornerstone product in BeiGene's solid tumor portfolio, with ongoing clinical development in over 33 countries and more than 15,800 participants enrolled [8] - The company plans to submit new indication applications for Baizean in the U.S. and China in the first half of 2026 [8] Future Outlook - BeiGene anticipates strong financial performance in Q4 2025 and throughout the year, highlighting its competitive advantages in clinical development and a differentiated R&D pipeline [9]